Heat shock proteins from Mycobacterium leprae and uses...

Details Heat shock proteins from Mycobacterium leprae and uses... Heat shock proteins from Mycobacterium leprae and uses...

2006-09-19

2009-11-24

Zeman, Robert A (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S184100, C424S278100, C424S281100, C424S282100

Reexamination Certificate

active

07622121

ABSTRACT:
The present invention is directed to heat shock proteins fromMycobacterium lepraeas well as their encoding polynucleotides and vectors and host cells containing these polynucleotides. These heat shock proteins and their encoding polynucleotides are useful in detection ofMycobacterium leprae. In addition, the heat shock protein can be used as an adjuvant in a pharmaceutical composition containing an antigen to induce or enhance the immune response against the antigen. Further, the heat shock protein may be used to treat atopic conditions or as a vaccine againstMycobacterium leprae. Alternatively, the heat shock protein can be used to form a fusion protein with an antigen to induce or enhance the immune response against the antigen.

REFERENCES:
patent: 4237224 (1980-12-01), Cohen et al.
patent: 5232833 (1993-08-01), Sanders et al.
patent: 5464750 (1995-11-01), Sanders et al.
patent: 5780034 (1998-07-01), Cohen et al.
patent: 5780246 (1998-07-01), Sanders et al.
patent: 5807690 (1998-09-01), Sanders et al.
patent: 6007821 (1999-12-01), Srivastava et al.
patent: 6214341 (2001-04-01), Thomas, Jr. et al.
patent: 6475490 (2002-11-01), Srivastava et al.
patent: 6495347 (2002-12-01), Siegel et al.
patent: 6497880 (2002-12-01), Wisniewski
patent: 6524584 (2003-02-01), Kensil
patent: 6524825 (2003-02-01), Mizzen et al.
patent: 6610659 (2003-08-01), Pramod
patent: 6645495 (2003-11-01), Kensil et al.
patent: 6657055 (2003-12-01), Siegel et al.
patent: 6797480 (2004-09-01), Srivastava
patent: 6797491 (2004-09-01), Neefe et al.
patent: 6900035 (2005-05-01), Mizzen et al.
patent: 6921534 (2005-07-01), Mizzen et al.
patent: 2003/0050469 (2003-03-01), Siegel et al.
patent: 2003/0099664 (2003-05-01), Wisniewski
patent: 2003/0148456 (2003-08-01), Mizzen et al.
patent: 2003/0170268 (2003-09-01), Neefe et al.
patent: 2004/0235741 (2004-11-01), Neefe et al.
patent: 2005/0037017 (2005-02-01), Mizzen et al.
patent: 2005/0089841 (2005-04-01), Siegel et al.
patent: 2005/0152917 (2005-07-01), Mizzen et al.
patent: 2005/0176672 (2005-08-01), Scheule et al.
patent: 2005/0202044 (2005-09-01), Mizzen et al.
patent: 0534858 (1993-03-01), None
patent: WO03058248 (2003-07-01), None
patent: WO2005025612 (2005-03-01), None
Brunello et al 2001 Journal of Clinical Microbiology vol. 39 No. 8 pp. 27-99-2806.
Greenspan et al. (Nature Biotechnology 7: 936-937, 1999).
Bowie et al (Science, 1990, 247:1306-1310).
Plotkin et al (Vaccines W.B. Saunders Company, 1988, p. 571.
Burgess et al., The Journal of Cell Biology, 111:2129-2138, 1990).
Botstein et al., “Construction of a Genetic Linkage Map in Man Using Restriction Fragment Length Polymorphisms,”Am. J. Hum. Genet.32:314-331 (1980).
Cole et al., “Massive Gene Decay in Leprosy Bacillus”Nature409:1007-11 (2001).
Groathouse et al., “Multiple Polymorphic Loci for Molecular Typing of Strains ofMycobacterium leprae, ” J. Clin. Micro42:1666-1672 (2004).
Kang et al., “Differential Production of Interleukin-10 and Interleukin-12 in Mononuclear Cells from Leprosy Patients with a Toll-Like Receptor 2 Mutation,”Immunology112:674-680, (2004).
Kurucz et al., “Ultrastructural Localization of Hsp-72 Examined with a New Polyclonal Antibody Raised Against the Truncated Variable Domain of the Heat Shock Protein,”Cell Stress&Chaperones4(2):139-152 (1999).
Genbank Accession No. Q546M0 (Sep. 13, 2005) [Retrieved on Jun. 26, 2007 retrieved from: <url: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=Protein&id=75504587>].
Oliveira et al., “Expression of Toll-like Receptor 2 on Human Schwann Cells: A Mechanism of Nerve Damage in Leprosy,”Infection and Immun.71:1427-1433 (2003).
Rastogi et al., “Species Specific Identification ofMycobacterium lepraeby PCR-Restriction Fragment Length Polymorphism Analysis of thehsp65Gene,”J. Clinical Microbiology37:2016-2019 (1999).
Ruiz et al., “Amplified-Fragment Length Polymorphism as a Complement to IS6110-Based Restriction Fragment Length Polymorphism Analysis for Molecular Typing ofMycobacterium tuberculosis,” J. Clin Micro41(10):4820-4822 (2003).
Sasaki et al., “Mycobacterium lepraeand Leprosy: A Compendium,”Microbiol. Immunol45(10):729-36 (2001).
Shin et al., “Variable Numbers of TTC Repeats inMycobacterium lepraeDNA from Leprosy Patients and Use in Strain Differentiation,”J. Clinical Microbiology38(12):4535-4538 (2000).
Truman et al., “Genotypic Variation and Stability of Four Variable-Number Tandem Repeats and Their Suitability for Discriminating Strains ofMycobacterium leprae,” J. Clinical. Micro42(6):2558-2565 (2004).
Vos et al., “AFLP: A New Technique for DNA Fingerprinting,”Nucleic Acids Res.23(21):4407-4414 (1995).
Welsh et al., “Fingerprinting Genomes Using PCR with Arbitrary Primers,”Nucleic Acids Res.18(24):7213-7218 (1990).
Williams et al., “DNA Polymorphism Amplified by Arbitrary Primers are Useful as Genetic Markers,”Nucleic Acids Res.18(22):6531-6535 (1990).
Young et al., “Leprosy, Tuberculosis, and the New Genetics,”J. Bacteriology.175:1-6 (1993).

Affiliated with

Also associated with

Rating

Heat shock proteins from Mycobacterium leprae and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heat shock proteins from Mycobacterium leprae and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heat shock proteins from Mycobacterium leprae and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4076266